Endologix Acquires Pounce Thrombectomy System From Surmodics

May 19, 2026—Endologix announced the acquisition of the Pounce thrombectomy system from Surmodics, expanding the company’s portfolio of peripheral vascular intervention technologies. According to the company, the transaction closed on May 18.

The Pounce thrombectomy system is an FDA-cleared, fully mechanical thrombectomy platform indicated for the nonsurgical removal of thrombi and emboli from peripheral arteries. The device incorporates a dual-basket design and nitinol collection funnel intended to facilitate clot retrieval without thrombolytics, aspiration, or capital equipment. Endologix stated that the system will continue to be marketed under its existing FDA clearance during a transition period.

The platform includes the commercially available Pounce LP, Pounce, and Pounce XL configurations, which are intended for use across a range of peripheral artery vessel sizes, including smaller and more distal vessels. Endologix said the acquisition broadens its offering for vascular interventionalists currently using the company’s Detour, Alto abdominal stent graft, and AFX2 endovascular abdominal aortic aneurysm systems for peripheral vascular disease treatment.

“The Pounce thrombectomy system is a strong strategic and clinical fit for Endologix,” commented John Liddicoat, MD, President and Chief Executive Officer of Endologix, in the company’s press release. “It serves the same physicians and patients we already work with every day and brings a clinically differentiated mechanical approach that complements our vascular intervention portfolio.”

Venkatesh Ramaiah, MD, FACS, said in the announcement, “I have used both Pounce and Endologix technologies in my practice, and bringing these solutions together under one organization makes a great deal of clinical sense.

“The Pounce fully mechanical thrombectomy system offers a grab-and-go solution that does not rely on thrombolytics or aspiration and complements Endologix’s portfolio of vascular technologies for the treatment of peripheral arterial disease. Together, these technologies provide physicians with additional flexibility when addressing thrombi and emboli in the peripheral arterial vasculature.” Dr. Ramaiah is Chief of Vascular and Endovascular Surgery at Pulse Cardiovascular Institute in Scottsdale, Arizona.

Endologix also stated that a core group of Surmodics team members supporting the Pounce platform will join the company as part of the acquisition.